In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.
Journal of clinical pathology（2023）
摘要
In-house testing for HRD can be reliably performed with commercially available next-generation sequencing assays.
更多查看译文
关键词
ovarian neoplasms,pathology, molecular,point-of-care testing
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要